 |
|||
|
New class of therapeutics: Spiegelmers
Development of a new class of therapeutics: Spiegelmers (mirror image RNA aptamers), with potential to replace monoclonal antibodies. First products target inflammatory diseases and back-of-the-eye conditions. Validating partnerships with Pfizer, Roche & Lilly. |
News :
07/07/2010 NOXXON to initiate Phase Ib clinical trial of MCP-1 inhibitor NOX-E36
06/28/2010 Noxxon Pharma AG announces management changes
05/27/2010 Noxxon Pharma raises € 33m in a Series D round of financing in which Seventure took part
05/04/2010 NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A12
12/03/2009 Noxxon Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company
10/14/2009 NOXXON Pharma AG announces excellent preliminary phase I trial results for Spiegelmer® NOX-E36 - good safety and pharmacodynamic profile and additional good subcutaneous bioavailability
06/08/2009 NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer
07/08/2008 Noxxon Pharma announces appointment of Lawrence E. Posner to its Board of Directors
06/12/2008 NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly and Co.
11/09/2007 NOXXON announces alliance with Roche
|
||
